NCT00516724 2025-04-11
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel
AstraZeneca
Phase 1 Completed
Clinical Trials
7 trialsNCT03168880 2025-04-09
TNBC
Tata Memorial Hospital
Phase 3 Active not recruiting
NCT01314833 2020-05-19
Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy
Fudan University
Phase 3 Completed
NCT00689156 2018-04-05
READ
Danish Breast Cancer Cooperative Group
Phase 3 Completed
NCT00912444 2016-11-22
NATT
Shanghai Jiao Tong University School of Medicine
Phase 3 Terminated
NCT02207361 2015-12-22
Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 4 Unknown
NCT01203267 2010-09-16
Weekly Paclitaxel Plus Carboplatin in Preoperative Treatment of Breast Cancer
Shanghai Jiao Tong University School of Medicine
Phase 2 Completed